Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research

Journal of Gastrointestinal Oncology

article

Checca Bakkers¹  Geert A. A. M. Simkens¹  Ignace H. J. T. De Hingh² 

[1] Department of Surgery, Catharina Cancer Institute;GROW - School for Oncology and Development Biology, Maastricht University

关键词: Systemic therapy;    cytoreductive surgery (CRS);    hyperthermic intraperitoneal chemotherapy (HIPEC);    peritoneal metastases (PM);    colorectal cancer;   

DOI  :  10.21037/jgo-20-133

学科分类：肿瘤学

来源: Pioneer Bioscience Publishing Company

【 摘 要 】

There is a lack of randomized or high-quality intention-to-treat cohort studies addressing the role of systemic therapy in addition to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) as part of the treatment of colorectal peritoneal metastases (PM). Therefore, the choice whether or not to treat patients with systemic therapy is currently mainly based on expert opinion. As a result, treatment with neoadjuvant and/or adjuvant systemic therapy is implemented in various ways around the world. The aim of this review was to provide an overview of recent insights with regard to the systemic treatment of PM of colorectal origin obtained from clinical studies and translational research.

【 授权许可】

Unknown